TAKEDA PHARMACEUTI SPON ADR EA REPR 0.5 ORD (TKPYY)

26.00
0.00 (0.00)
OTC
Prev Close 26.00
Open 25.61
Day Low/High 25.61 / 26.01
52 Wk Low/High 19.96 / 26.17
Volume 119.49K
Exchange OTC
Shares Outstanding 1581.11B
Market Cap 41.11B
Div & Yield N.A. (N.A)

Latest News

New Real-World Analyses Support Effectiveness And Safety Of Entyvio® (vedolizumab) For Ulcerative Colitis And Crohn's Disease

Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium

Takeda Receives Award For Supporting Employees Who Serve In Military

Company Earns Outstanding Employer Distinction; Individual Employee Receives Patriot Award

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal

Takeda Acquires Ariad Pharmaceuticals in $5.2 Billion Deal

Shares of Ariad Pharmaceuticals soared Monday after Japan's Takeda Pharmaceutical offered to buy the leukemia drug maker.

A Very Happy New Year for Investors in Japan

A Very Happy New Year for Investors in Japan

The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.

Takeda Presents 17 Abstracts At The 2016 Advances In Inflammatory Bowel Diseases (AIBD) Annual Conference

Takeda Presents 17 Abstracts At The 2016 Advances In Inflammatory Bowel Diseases (AIBD) Annual Conference

Data to feature additional insights into vedolizumab and elements of inflammatory bowel disease (IBD)

SEC Discloses Correspondence Over Valeant's Accounting Practices

SEC Discloses Correspondence Over Valeant's Accounting Practices

The SEC has released correspondence between the agency and Valeant over concerns about its tax accounting and non-GAAP reporting measures.

How to Trade Wednesday's Most Active Stocks -- Chesapeake Energy, American Eagle, More

How to Trade Wednesday's Most Active Stocks -- Chesapeake Energy, American Eagle, More

Here's a technical look on how to trade some of the most active stocks on the market today.

Valeant Plummets on Reports of Salix Takeover Breakdown

Valeant Plummets on Reports of Salix Takeover Breakdown

Valeant shares fell Wednesday on news that talks with Takeda to take over Valeant's Salix unit have broken down.

Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness And Safety In Inflammatory Bowel Disease In More Than 50 Real-World Studies

Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness And Safety In Inflammatory Bowel Disease In More Than 50 Real-World Studies

In patients with moderate to severely active ulcerative colitis or Crohn's disease, review of real-world data supports outcomes of vedolizumab clinical trial program

Buy These 4 Stocks and Beat Biotech's Slump

Buy These 4 Stocks and Beat Biotech's Slump

Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.

Additional Interim Data Supporting Long-Term Use Of Vedolizumab In Patients With Ulcerative Colitis And Crohn's Disease Published In Journal Of Crohn's And Colitis

Additional Interim Data Supporting Long-Term Use Of Vedolizumab In Patients With Ulcerative Colitis And Crohn's Disease Published In Journal Of Crohn's And Colitis

Interim analyses shows clinical benefits with long-term vedolizumab treatment regardless of prior tumor necrosis factor (TNF) antagonist exposure

Four Stellar Stocks to Beat the Biotech Slump

Four Stellar Stocks to Beat the Biotech Slump

Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum

Will Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals?

Will Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals?

Takeda Pharmaceuticals (TKPYY) CEO Christophe Weber said the company is exploring deals outside of Japan, particularly in the U.S.

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.